Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...
Company
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...
Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services
Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...
Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture
China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...
Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...
Gilead Sciences Announces $11 Billion Investment in US Expansion
US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...
Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...
Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...
Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area
US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...
Insilico Medicine Files for IPO to Leverage AI in Drug Discovery
China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...
Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages
US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...
Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment
US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....
Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership
China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...
Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang
China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...
Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....
BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...
Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales
US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...